What India’s 2019 cancer drug margin cap teaches us about medicine prices
In 2019, India’s drug price regulator capped the trade margin on 42 cancer medicines at 30%. Prices of 526 brands came down, many by more than half and some by about 90%, with estimated patient savings of ₹984 crore a year. The lesson is that the gap between what a medicine costs to supply and its MRP is set upstream, and can be narrowed without touching who sells it.
Key facts at a glance
| What happened | NPPA used Paragraph 19 of DPCO 2013 to cap trade margins at 30% on 42 non-scheduled anti-cancer medicines, in 2019. |
| Result | Reduced MRPs on 526 brands; estimated savings of ₹984 crore a year (PIB, November 2020). |
| Why it matters now | It is a working Indian precedent for the current debate on medicine prices. |
What a trade margin cap does
A trade margin is the gap between the price at which a manufacturer sells to the stockist (price to stockist, or PTS) and the MRP. For many specialty medicines, that gap had grown very large, because manufacturers competed for distribution by offering bigger margins rather than lower prices. A 30% cap meant the MRP could be no more than 30% above the price to stockist. Manufacturers had to lower MRPs to comply.
The numbers
According to the government’s own review (PIB, 6 November 2020):
| Price reduction | Number of brands |
|---|---|
| 75% or more | 63 |
| 50% to 75% | 167 |
| 25% to 50% | 169 |
| Up to 25% | 127 |
| Total | 526 |
Two examples from that review: Erlotinib 150 mg fell from ₹9,999 to ₹891.79, a reduction of about 91%. Pemetrexed 500 mg fell from ₹25,400 to ₹2,509, about 90%.
Five lessons for today
1. Fix the gap where it is created
The cap worked on the manufacturer-to-trade gap. Every seller, whether a chemist, an online pharmacy or a hospital, then sold from a lower MRP. Nobody had to be singled out.
2. Start narrow
Cancer medicines were a sensible pilot: high prices, high patient burden, and large margins. A narrow first step made results easy to measure.
3. Publish the results
NPPA published brand-level outcomes. That transparency is what lets us discuss the policy with numbers six years later.
4. Watch availability
Any price action needs monitoring for supply gaps and brand withdrawals. Price falls only help if the medicine stays on shelves.
5. Communicate the change to patients
Many patients never knew prices had fallen. Hospitals and pharmacies that explained the change built goodwill. That communication habit is worth building in now, see my checklist for when regulation makes headlines.
How this connects to the current debate
In September 2026, questions about medicine markups in private hospitals reached the Supreme Court. The 2019 cap shows the problem can be addressed upstream, through the trade margin, which applies equally to every channel. I cover the wider context in hospital medicine prices: what the debate misses and the basics in who sets the MRP on your medicine.
This is a policy explainer, not legal, medical or investment advice. Figures are from government sources linked above; see NPPA for current notifications.
Questions people ask
In 2019, NPPA capped the trade margin at 30% on 42 non-scheduled anti-cancer medicines, so their MRP could not exceed the price to stockist by more than 30%.
526 brands had their MRPs reduced, according to a PIB release in November 2020.
63 brands fell by 75% or more, 167 by 50% to 75%, 169 by 25% to 50%, and 127 by up to 25%.
The government estimated savings of about ₹984 crore a year.
Paragraph 19 of the Drugs (Prices Control) Order, 2013, which lets the government act on prices in extraordinary circumstances in the public interest.
The price at which a manufacturer sells a medicine to the distributor or stockist. The trade margin is the gap between this and the MRP.
The cap applied to the product MRP, so every seller, including hospitals, sold from the lower MRP.
42 non-scheduled anti-cancer medicines, such as Erlotinib and Pemetrexed, chosen because of high prices and high trade margins.
The 2019 action focused on cancer medicines. Any extension would require fresh notification by the government.
Because the current debate on medicine markups is about the same gap between supply cost and MRP, and 2019 showed one way to address it.
Availability should always be monitored after price action. The published review focused on price reductions and savings.
Read my takes first in Google Search
